«We have had a complete response in eight out of twelve patients,» says Brenner, who did the work in collaboration with Baylor College of
Medicine hematologists Catherine Bollard and Helen Heslop.
Not exact matches
He is a principal investigator of the PHRI, an associate professor of
medicine at McMaster and a
hematologist at HHS.
«Our findings suggest that PRMT5 is a possible prognostic factor and therapeutic target for glioblastoma, and they provide a rationale for developing agents that target PRMT5 in this deadly disease,» says co-corresponding author Robert A. Baiocchi, MD, PhD, associate professor of
medicine and a
hematologist at the OSUCCC — James who is also collaborating on an Ohio State effort to develop a PMRT5 inhibitor.
Dr. Wang is also an Assistant Professor, Faculty of
Medicine, University of Toronto and a
Hematologist at Toronto General Hospital, UHN.
«There's a price to pay if you prevent too much,» says Leo Luznik, an oncologist and
hematologist at Johns Hopkins University School of
Medicine in Baltimore, Maryland, «and unfortunately we don't have a thermostat that we can turn up or down» to get the T cell suppression right.
«Until now, physicians have taken a «wait and see» approach to antiviral therapies following transplantation,» says Toor, a
hematologist - oncologist in the Bone Marrow Transplant Program and member of the Developmental Therapeutics research program at VCU Massey Cancer Center as well as professor in the Division of Hematology, Oncology and Palliative Care at the VCU School of
Medicine.
At the University of Chicago
Medicine campus, the
hematologists / oncologists on our multiple myeloma team are nationally known experts in the treatment of this disease.